Bayer AG and Johnson & Johnson Anti-Clot Drug Misses Goal Of Midstage Study
NEW ORLEANS, Nov 10 (Reuters) - An experimental blood clot preventer being developed by Bayer AG (BAYG.DE: Quote, Profile, Research, Stock Buzz) and Johnson & Johnson (JNJ.N: Quote, Profile, Research, Stock Buzz) missed its primary efficacy goal in a mid-stage study in patients with acute coronary syndrome and led to more bleeding than a placebo, according to data released on Monday.